VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
The Company’s lead product candidate, oral VXM01, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors.
VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer.
The Company has several additional product candidates at various stages of preclinical development targeting a variety of tumor targets and neoantigens.
VAXIMM has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate avelumab, a human anti-PD-L1 antibody, in combination with VXM01 in glioblastoma and colorectal cancer. The Company also has entered into a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs.
VAXIMM’s investors include BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital.
VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.
VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise.